Hims & Hers: A Forced Pivot Tests the Telehealth Model

Telehealth firm Hims & Hers shifts strategy after FDA action, now selling branded Wegovy. Despite strong 2025 revenue of $2.35B, stock is down 40% amid intense GLP-1 competition and a push into a broader health tech platform.

The telehealth provider Hims & Hers is navigating a fundamental business model shift, compelled by a regulatory crackdown on compounded weight-loss drugs. The U.S. Food and Drug Administration (FDA) has forced the company to pull its own compounded semaglutid pill from the market, pushing it into direct competition with pharmaceutical giants by distributing the branded drug Wegovy instead.

This strategic upheaval arrives even as the company posts robust operational results. For the full year 2025, Hims & Hers closed profitably with revenue of $2.35 billion and net income of $128.37 million. Its workforce grew 49 percent to 2,442 employees. The fourth quarter alone saw revenue jump 28 percent to $617.82 million.

Yet, investor sentiment has been brutal. The stock has lost roughly 40 percent of its value since the start of the year, currently trading at $21.36. Over the past twelve months, shares have swung between $13.74 and $70.43. While some analysts, citing valuation models like the BlackGoat analysis which calculates a fair value of $86.09, believe the current $4.87 billion market capitalization is too low, the majority maintain a 'hold' stance with an average price target of $24.00.

The competitive landscape is intensifying rapidly. Novo Nordisk's recent pricing adjustment for oral GLP-1 treatments adds direct pressure. Self-pay patients now face monthly costs ranging from $149 for lower doses to $299 for higher concentrations of Wegovy pills, with a 4mg dose set at $199. Furthermore, insurance coverage for branded drugs can reduce a patient's cost to as little as $25 per month, undermining the appeal of cheaper alternatives.

In response to shrinking margins and stricter FDA scrutiny of compounded preparations, Hims & Hers is accelerating a transformation into a broader technology-based health platform. The company is moving beyond imitation products to seek official partnerships for GLP-1 medications and is betting that integrated digital health services will differentiate it from rivals like Amazon Pharmacy and Eli Lilly, which are expanding their direct-to-consumer obesity drug businesses.

Key initiatives in this platform shift are underway. They include the launch of "Labs" for blood-based biomarker tests focused on heart health and metabolism, the integration of the acquired Canadian digital health platform Livewell, an expansion into cancer screening and holistic lab services, and the purchase of YourBio Health for needle-free capillary blood collection. Artificial intelligence is positioned as the future operating system for enabling precise diagnoses and personalized treatments at scale.

All eyes are now on the upcoming quarterly report, scheduled for release after the market closes on May 11. This will provide the first concrete data on the impact of the forced strategy change. Analysts expect Q1 revenue of approximately $621.4 million, representing year-over-year growth of six percent. Investors will scrutinize subscriber growth and, critically, margin development as management works to offset an estimated $65 million headwind resulting from new shipping regulations for compounded medications. The report will be a crucial test of whether the company's high-stakes pivot can begin to close the wide discount to its perceived fair value.